-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
TARS:NSD- (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 25.26Change
-0.55 (-2.13)%Market Cap
USD 1.03BVolume
0.59MVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Biotechnology |
Last Closing
USD 25.26Change
-0.55 (-2.13)%Market Cap
USD 1.03BVolume
0.59MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc |
N/A |
USD 122.24B |
REGN | Regeneron Pharmaceuticals Inc |
N/A |
USD 115.08B |
MRNA | Moderna Inc |
N/A |
USD 51.07B |
ALNY | Alnylam Pharmaceuticals Inc |
N/A |
USD 28.20B |
ARGX | argenx NV ADR |
N/A |
USD 26.78B |
BNTX | BioNTech SE |
N/A |
USD 20.40B |
BGNE | BeiGene Ltd |
N/A |
USD 17.50B |
GMAB | Genmab AS |
N/A |
USD 16.65B |
BMRN | Biomarin Pharmaceutical Inc |
N/A |
USD 15.98B |
RPRX | Royalty Pharma Plc |
N/A |
USD 15.90B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
SLX | VanEck Steel ETF | 4.59 % | 0.56 % |
N/A |
USD 0.09B |
PYZ | Invesco DWA Basic Materia.. | 3.86 % | 0.60 % |
N/A |
USD 0.06B |
XMHQ | Invesco S&P MidCap Qualit.. | 2.11 % | 0.25 % |
N/A |
USD 5.26B |
IVOG | Vanguard S&P Mid-Cap 400 .. | 1.24 % | 0.20 % |
N/A |
USD 1.01B |
IJK | iShares S&P Mid-Cap 400 G.. | 1.24 % | 0.24 % |
N/A |
USD 9.54B |
QVMM | Invesco Exchange-Traded F.. | 0.71 % | 0.00 % |
N/A |
USD 0.30B |
DEUS | Xtrackers Russell US Mult.. | 0.68 % | 0.18 % |
N/A |
USD 0.15B |
ONEO | SPDR® Russell 1000 Momen.. | 0.68 % | 0.20 % |
N/A |
USD 0.15B |
SPY4:LSE | SSgA SPDR ETFs Europe I P.. | 0.65 % | 0.00 % |
N/A |
USD 1.94B |
IJH | iShares Core S&P Mid-Cap .. | 0.64 % | 0.07 % |
N/A |
USD 82.98B |
IVOO | Vanguard S&P Mid-Cap 400 .. | 0.64 % | 0.15 % |
N/A |
USD 1.96B |
ZMID-F:CA | BMO S&P US Mid Cap Index .. | 0.64 % | 0.00 % |
N/A |
CAD 2.03M |
ZMID-U:CA | BMO S&P US Mid Cap Index .. | 0.64 % | 0.00 % |
N/A |
N/A |
BBMC | JPMorgan BetaBuilders U.S.. | 0.46 % | 0.00 % |
N/A |
USD 1.66B |
BBP | Virtus LifeSci Biotech Pr.. | 0.00 % | 0.79 % |
N/A |
USD 0.02B |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 24.74% | 80% | B- | 86% | B+ | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 24.74% | 80% | B- | 86% | B+ | ||
Trailing 12 Months | |||||||
Capital Gain | 41.35% | 84% | B | 88% | B+ | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 41.35% | 84% | B | 88% | B+ | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 3.19% | 62% | D | 54% | F | ||
Dividend Return | 3.19% | 61% | D- | 50% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 51.33% | 55% | F | 33% | F | ||
Risk Adjusted Return | 6.22% | 64% | D | 45% | F | ||
Market Capitalization | 1.03B | 82% | B | 73% | C |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers median on a price to book value basis.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector